A151216, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
NCT#02194738
A081801*, Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
NCT#0426784
E4512*, A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
NCT#02201992
* Participants must be enrolled in A151216 to enroll in this study.
